PTX: Continued promising results in PTX-100 TCL trial
PRESCIENT THERAPEUTICS LIMITED
- PTX-100 shows positive response rates in patients with relapsed and refractory T cell lymphomas
- 7 out of 10 patients had durations of response exceeding standard of care
- Modest increase in patient numbers planned to create regulatory package following recent Orphan Drug Designation from FDA
2023-03-16 09:53:00